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University, Lyon, FranceIntroduction: The impact of preformed donor-specific anti–human leukocyte antigen (HLA) antibodies
(pDSAs) after combined liver-kidney transplantation (CLKT) is still uncertain.
Methods: We conducted a retrospective study in 8 European high-volume transplant centers and inves-
tigated the outcome of 166 consecutive CLKTs, including 46 patients with pDSAs.
Results: Patient survival was lower in those with pDSAs (5-year patient survival rate of 63% and 78% with or
without pDSA, respectively; P ¼ 0.04). The presence of pDSAs with a mean fluorescence intensity (MFI) $ 5000
(hazard ratio 4.96; 95% confidence interval: 2.3–10.9; P < 0.001) and the presence of 3 or more pDSAs (hazard
ratio 6.5; 95% confidence interval: 2.5–18.8; P ¼ 0.05) were independently associated with death. The death-
censored liver graft survival was similar in patients with or without pDSAs. Kidney graft survival was compa-
rable in both groups. (The 1- and 5-year death-censored graft survival rates were 91.6% and 79.5%, respectively,
in patients with pDSAs and 93% and 88%, respectively, in the donor-specific antibody [DSA]-negative group, P¼
not significant). Despite a higher rate of kidney graft rejection in patients with pDSAs (5-year kidney graft survival
rate without rejection of 87% and 97% with or without pDSAs, respectively; P ¼ 0.04), kidney function did not
statistically differ between both groups at 5 years post-transplantation (estimated glomerular filtration rate 45 
17 vs. 57 29 ml/min per 1.73 m2, respectively, in patients with and without pDSAs). Five recipients with pDSAs
(11.0%) experienced an antibody-mediated kidney rejection that led to graft loss in 1 patient.
Conclusion: Our results suggest that CLKT with pDSAs is associated with a lower patients’ survival despite
good recipients’, liver and kidney grafts’ outcome.
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he pathogenicity of DSAs differs according to the
transplanted organ. After kidney transplantation
with pDSAs, antibody-mediated rejection (AMR) is a
common complication, and long-term kidney allograftKidney International Reports (2020) 5, 2202–2211
A Del Bello et al.: CLKT With or Without pDSA CLINICAL RESEARCHsurvival is poorer compared with that observed in pa-
tients transplanted without pDSAs.1,2 Conversely, the
incidence of acute AMR after liver transplantation
with pDSAs is relatively infrequent,3 and early graft
failure related to AMR is exceptional.4 There is no
consensual strategy regarding the clinical management
of CLKT in patients with pDSAs. Considering that in
this context hyperacute humoral rejection does not
usually occur, the presence of pDSAs is not considered
to be a contraindication for CLKT. Nevertheless, several
studies have reported a lower kidney graft survival af-
ter CLKT in case of an initial positive crossmatch
(XM).5,6 Data concerning CLKT with pDSAs and nega-
tive XM are scarce. Moreover, few data are available
concerning the use of induction therapy in this
context. After HLA-incompatible kidney transplanta-
tion, most centers use rituximab and polyclonal
antibodies.7 After HLA-incompatible liver transplanta-
tion, a potential interest of polyclonal antibodies has
been suggested from some8 but not all studies,3
whereas rituximab does not seem to improve the
outcome.3
The aims of the present large retrospective, multi-
center study were to assess the outcome of liver and
kidney transplants in the setting of CLKT with pDSAs
and to evaluate the impact of induction therapy.PATIENTS AND METHODS
Study Population
All CLKTs with anti-HLA screening with the Luminex
single antigen (Luminex SA, Canoga Park, CA) avail-
able at transplantation from the following 8 European
transplant centers were included in this retrospective
study (N ¼ 166): Lyon University Hospital
(2002–2018, n ¼ 41), Toulouse University Hospital
(2008–2019, n ¼ 34), Montpellier University Hospi-
tal (2010–2015, n ¼ 22), Bellvitge University Hospital
(2002–2010, n ¼ 21), Kremlin-Bicètre University
Hospital (2010–2015, n ¼ 17), Strasbourg University
Hospital (2009–2018, n ¼ 15), Tours University Hos-
pital (2011–2016, n ¼ 14), and Bordeaux University
Hospital (2012–2015, n ¼ 2). All transplants were from
donation after brain death.
In addition to the comparison of the outcome of
CLKT patients with or without pDSAs, we compared
the rejection rate, kidney histologic features observed
in protocol biopsies obtained at 1 year, and graft sur-
vival of CLKT patients with pDSAs to those observed
in a group of kidney transplant alone (KTA) recipients
with pDSAs who were grafted in Toulouse between
2008 and 2017 (n ¼ 86) (Table 1). Furthermore, we
compared patient and graft survival rates of CLKT
patients with pDSAs with those observed in a group ofKidney International Reports (2020) 5, 2202–2211liver transplant alone recipients with pDSAs who were
grafted in Toulouse between 2008 and 2018 (n ¼ 38)
(Table 1).
According to French Law (loi Jardé), anonymous
retrospective studies do not require institutional re-
view board approval.
Immunologic Analysis
The presence of pDSAsM or de novo DSAs was tested
using Labscreen Single Antigen technology (One
Lambda, Canoga Park, CA) in all centers, except in
Lyon. The Labscreen Single Antigen determined the
specificity of class I HLAs in A/B and class II in DR/DQ
IgG antibodies in the recipients’ sera (centrifuged at
10,000g for 10 minutes) according to the manufacturer’s
instructions. The presence and specificity of antibodies
were then detected using a Labscan 100 (One Lambda,
Canoga Park, CA), and the mean fluorescence (baseline
value) for each sample in each bead was evaluated. A
baseline mean fluorescence intensity value of >1000
was considered positive. The immunodominant DSA
was the DSA with the highest MFI at transplantation.
The MFI sum was the sum of all A/B/DR/DQ MFI of the
DSAs.
In Lyon, pDSAs were detected using the Lifecodes
single-antigen technology (LMX Deluxe; Immucor,
Norcross, GA). The Lifecodes single antigen (LSA class
I/II) determined the specificity of class I HLAs in A/B
and class II in DR/DQ IgG antibodies in the recipients’
sera according to the manufacturer’s instructions. The
presence and specificity of antibodies were then
detected, and the MFI for each sample in each bead was
evaluated. An MFI value of >1000 was considered
positive. In order to compare the MFI obtained with
the Lifecodes single-antigen technology and those ob-
tained with Labscreen Single Antigen technology, we
doubled the MFI obtained with the Lifecodes SA
because it was recently suggested in a recent publica-
tion.9 All XMs were performed by lymphocytotoxicity.
Pathologic Analysis
All rejection episodes were biopsy proven and classi-
fied according to the liver or renal Banff classifica-
tion.9–11 The 1-year systematic kidney biopsies were
analyzed and classified according to the renal Banff
classification.9
Statistical Analyses
Reported values represent the means ( SD) or
medians (ranges). Quantitative variables were
compared using the Mann-Whitney nonparametric
test. Categoric variables are expressed as percent-
ages and compared between groups using the chi-
square test or, if appropriate, the Fisher exact2203





















Recipient’s age, yr (mean) 51  13 50  13 0.58 49  13 0.73 53  10 0.70
Recipient’s sex, male (%) 74 (62) 26 (57) 0.55 37 (43) 0.35 6 (16) <0.001
Initial liver disease 0.10 — — <0.001
Alcohol 31 (26) 6 (13) 12 (32)
Viral (HBV, HCV) 17 (14) 8 (17) 8 (21)
PKD 23 (19) 14 (31) 0
Autoimmune (PCS, AIH, PBC) 8 (7) 0 8 (21)
Primitive hyperoxaluria 8 (7) 6 (13) 0
Other 33 (27) 12 (26) 10 (26)
MELD score at transplantation,
median (minimum–maximum)
24 (6–40) 23 (6–40) 0.09 — — 24 (6-40) 0.56
Liver retransplantation, yes (%) 17 (14) 5 (11) 0.76 — — 5 (13) 0.62
Positive HBV-DNA at
transplantation, yes (%)
1 (1) 0 >0.99 0 >0.99 0 >0.99
Positive HCV-DNA at
transplantation, yes (%)
12 (10) 4 (9) >0.99 0 0.01 6 (16) 0.34
Liver cold ischemia time (min),
mean ( SD)
430  180 400  200 0.20 413  146 0.62
Initial kidney disease (%) 0.25 <0.001 — —
IgA nephropathy 23 (19) 6 (13) 9 (11)
Diabetes 12 (10) 7 (15) 6 (7)
PKD/urinary tract abnormalities 24 (20) 13 (28) 32 (37)
Hyperoxaluria 13 (11) 8 (18) 0
Vascular 0 0 8 (9)
Unknown/other 48 (40) 12 (26) 31 (36)
Kidney retransplantation,
yes (%)
17 (14) 9 (20) 0.54 54 (63) <0.001 — —
Kidney cold ischemia time
(minimum), mean ( SD)
738  300 716  253 0.40 191  369 0.01 — —
Donor age, yr (mean) 45  16 48  15 0.18 49  15 0.22 54  19 0.56
HLA mismatches
Class I 3.1  1.2 3.3  1.1 0.18 4.4  1.3 0.50 3.2  1.0 0.50
Class II 2.5  1.5 2.9  1.3 0.15 2.0  1.2 0.30 3.0  0.9 0.45
Positive anti-HLA antibodies,
yes (%)
27 (23) 46 (100) <0.001 86 (100) >0.99 38 (100) >0.99
Positive pDSAs at transplantation,
yes (%)
— 46 (100) — 86 (100) >0.99 38 (100) >0.99
Anti–class I DSA — 19 (41) 50 (58) 0.07 12 (32) 0.38
Anti–class II DSA — 19 (41) 28 (33) 0.40 11 (29) 0.26
Anti–class I and II DSA — 8 (18) 8 (9) 0.22 15 (39) 0.03
Number of pDSAs, median
(minimum–maximum)
— 1 (1-7) 1 (1-3) 0.15 2 (1–7) 0.20
Mean MFI of the ID pDSA at Tx 6000  5500 4100  4000 0.77 9440  6430 0.01
Mean sum of MFI pDSA at Tx — 15,600  26,700 5600  8200 0.41 44,000  50,000 <0.001
Positive LCT-XM at transplantation,
y (%)
— 13 (28) 2 (2) <0.001 10 (26) >0.99
Positive T-cell crossmatch — 0 0
Positive B-cell crossmatch 1 (2) 0
Positive T- and B-cell
crossmatch
12 (26) 2 (2) <0.001
Induction therapy, yes (%) 95 (79) 44 (96) 0.01 86 (100) 0.11 35 (92) 0.65
Polyclonal antibodies 35 (29) 39 (85) <0.001 86 (100) <0.001 27 (71) 0.18
Anti-IL2R blockers 60 (50) 7 (15) <0.001 0 0.003 8 (21) 0.57
Rituximab, y (%) 0 7 (15) <0.001 64 (74) <0.001 15 (39) 0.01
Apheresis sessions, yes (%) 0 5 (11) <0.001 46 (53) <0.001 5 (13) 0.75
i.v. Ig, yes (%) 0 10 (22) <0.001 21 (24) 0.82 4 (10) 0.24
(Continued on following page)
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CNI use, yes (%) 120 (100) 46 (100) >0.99 86 (100) >0.99 38 (100) >0.99
Tacrolimus, yes (%) 95 (79) 36 (78) >0.99 86 (100) <0.001 37 (97) 0.01
Cyclosporin A, yes (%) 25 (21) 10 (22) >0.99 0 <0.001 1 (3) 0.01
MPA, yes (%) 120 (100) 46 (100) >0.99 86 (100) >0.99 38 (100) >0.99
Steroids, yes (%) 119 (99) 43 (100) >0.99 86 (100) >0.99 38 (100) >0.99
1-year post-transplant
immunosuppression
CNI use, y (%) 102a (91) 39b (100) 0.33 73c (97) 0.83 31d (100) >0.99
Tacrolimus, yes (%) 84 (82) 37 (94) 0.10 73 (97) 0.80 31 (100) 0.49
Cyclosporin A, yes (%) 18 (18) 2 (6) 0.10 0 0.19 0 0.49
MPA, yes (%) 95 (85) 28 (72) 0.66 65 (87) 0.33 31 (100) 0.001
mTORi, yes (%) 3 (8) 0 0.57 10 (13) 0.06 0 0
Azathioprine, yes (%) 3 (8) 0 0.57 0 >0.99 0 0
Belatacept, yes (%) 0 0 >0.99 2 (3) >0.99 0 0
Steroids, yes (%) 80 (71) 18 (46) 0.006 75 (100) <0.001 31 (100) <0.001
AIH, autoimmune hepatitis; BPC, biliary primary cirrhosis; CKLT, combined liver-kidney transplantation; CNI, calcineurin inhibitor; DSA, donor-specific antibody; HBV, hepatitis B virus;
HCV, hepatitis C virus; ID, immunodominant; KTA, kidney transplant alone; LCT-XM, lymphocytotoxicity crossmatch; MFI, mean fluorescence intensity; MPA, mycophenolic acid; mTORi,
mTOR inhibitors; PCS, primary cholangitis sclerosis; PKD, polycystic kidney disease; TX, transplantation.
aEight patients died during the first year post-transplant.
bSeven patients died during the first year post-transplant.
cFour patients died, and 7 additional patients returned to dialysis during the first year post-transplant.
dSeven patients died during the first year post-transplant.
A Del Bello et al.: CLKT With or Without pDSA CLINICAL RESEARCHtest. A P value < 0.05 was considered statistically
significant. The cumulative probability of patient or
graft survival or acute rejection was calculated
using the Kaplan-Meier method. A Cox proportional
hazard analysis was used to identify predictive
factors for recipient survival and acute kidney graft
rejection. Variables with a P value < 0.10 in the
univariate analysis as well as the transplant center,
the persistence of pDSAs after transplantation, and
factors known to be associated with the “acute
rejection” and “recipient survival” outcomes
(including the occurrence of biliary complications
and liver retransplantation) were entered in the
stepwise multivariable model with backward elim-
ination. Statistical analyses were performed using
XLSTAT software (Addisoft, Paris, France).RESULTS
Study Population and Initial Immunosuppres-
sive Strategy
The main characteristics of the patients who were
included are presented in Table 1. Forty-six of the 166
(28%) CLKT recipients included in the study presented
with pDSAs at transplantation. Alcoholic liver disease
was the main indication for transplantation in patients
without pDSAs, whereas patients with pDSAs pre-
sented principally with polycystic kidney disease.
Kidney retransplantations were more frequent in pa-
tients with pDSAs (26% vs. 12% in patients without
pDSAs, P ¼ 0.008).
Kidney International Reports (2020) 5, 2202–2211Induction therapy was more frequently used in pa-
tients with pDSAs and was mainly based on the use of
polyclonal antibodies, whereas anti–interleukin-2 re-
ceptor blockers were more frequently used in patients
without pDSAs. The initial and maintenance immuno-
suppression was similar in both groups.
Compared with KTA recipients with pDSAs, CLKT
recipients with pDSAS had a positive XM at trans-
plantation significantly more often. Conversely, they
received polyclonal antibodies, rituximab, and
tacrolimus-based immunosuppression less often; had
steroid withdrawal after transplantation; and had un-
dergone apheresis less often.
Patient Survival According to the Presence of
pDSAs
Fifteen patients (7 recipients with pDSAs [15.2%] and 11
recipients without pDSAs [9.2%]) died during the first
year post-transplantation (P ¼ 0.40). In patients with
pDSAs, deaths were related to infection (bacterial
pneumonia [n ¼ 2], invasive aspergillosis [n ¼ 1], and
bile duct infection [n ¼ 2]) and heart failure (related to
pulmonary embolism [n ¼ 1] and myocardial infarction
[n ¼ 1]). In patients without pDSAs, the causes of death
were related to infection (bacterial pneumonia [n ¼ 1],
invasive aspergillosis [n ¼ 2], and bile duct infection
[n ¼ 4]), cancer (n ¼ 1), and heart failure (myocardial
infarction [n ¼ 3]). During the follow-up, patient sur-
vival was significantly lower in patients with pDSAs
compared with patients without pDSAs (Figure 1).
















CLKT without pDSAs (n=120)
CLKT with pDSAs (n=46)
pDSA n=46            29              17             12              6                 4
no pDSA n=120    97              68             50             39               35
Log-rank p= 0.04
Variable HR 95% CI p
pDSA with a MFI >5,000 4.96 2.3- 10.9 <0.001
3 or more pDSAs 4.7 1.6- 13.9 0.005
Figure 1. Patient survival according to the presence of preformed donor-specific anti–human leukocyte antigen antibodies (pDSAs). Kaplan-
Meier recipient analysis and Cox proportional regression model according to the presence of pDSAs after combined liver-kidney trans-
plantation (CLKT). CI, confidence interval; HR, hazard ratio.
CLINICAL RESEARCH A Del Bello et al.: CLKT With or Without pDSAfollow-up, there was a trend of a higher rate of positive
T- and/or B-cell XM at transplantation (6/12 vs. 7/34,
P ¼ 0.07), a higher number of pDSAs (median 1.5 [range
1–7] vs median 1 (range 1–5), P ¼ 0.07), and a higher
MFI of the immunodominant DSA (median 8000 [range
1200–17,000] vs. 4000 [1000–15,000], P ¼ 0.07). How-
ever, we did not find any difference concerning the class
of DSAs (i.e., 8/12 patients who died and 19/34 patients
who did not for anti–class I DSAs [P ¼ 0.73]; 8/12 pa-
tients who died and 19/34 patients who did not for anti–
class II DSAs (P ¼ 0.73]; and 4/34 patients who died and
4/12 patients who did not for both anti–class I and II
DSAs [P ¼ 0.18]). The sum of pDSA MFIs at trans-
plantation was also similar in both groups (i.e., 9000
[range 1200–67,000] vs. 5000 [1000–94,000], P ¼ 0.18).
We assessed the predictive factors for death by means
of a Cox proportional regression model with backward
elimination according to the presence of pDSAs, the
transplant center, the persistence of pDSAs after trans-
plantation, the XM (T and/or B cells) result at trans-
plantation, the initial liver disease, the occurrence of
kidney rejection after transplantation, kidney retrans-
plantation, the occurrence of biliary complications after
liver transplantation, and the presence of liver retrans-
plantation. After adjusting for these factors, the pres-
ence of a pDSA with an MFI higher than 5000 (hazard
ratio 4.96; 95% confidence interval: 2.3–10.9; P < 0.001)
and a number of 3 or more pDSAs (hazard ratio 4.7; 95%
confidence interval: 1.6–13.9; P ¼ .005) were the pre-
dictive factors identified in this model.Liver Transplant Outcome
Three liver transplant patients with pDSAs presented
with end-stage liver failure 6 months (range 3–16
months) post-transplantation. The causes of liver fail-
ure were arterial thrombosis resulting in ischemic2206cholangitis in 3 cases. One patient was retransplanted,
and 2 patients died while on the waiting list.
Four patients without pDSAs evolved to end-stage
liver failure 37 months (range 4–92 months) post-
transplantation. The causes of liver failure were
ischemic cholangitis in 3 cases, which were success-
fully retransplanted, and the cause was unknown in
the last recipient who rapidly died from sepsis.
The biopsy-proven liver rejection rate was similar in
both groups (2% and 6.5%, respectively, at 5 years in
patients with and without pDSAs; P ¼ not significant;
Supplementary Figure S1). All of these cases were ste-
roid sensitive. During the follow-up, no CLKT recipient
presented histologic features of antibody-mediated
liver rejection. No liver failure related to graft rejec-
tion was observed during the follow-up period.
Patients’ survival did not differ after CLKT or liver
transplant alone with pDSAs (Supplementary
Figure S2). Ductal complications occurred in 7 (15%)
patients with pDSAs and 20 (17%) patients without
pDSAs (P ¼ 0.43).Kidney Transplant Outcome in CLKT recipients
During the follow-up, death-censored graft survival
was similar in CLKT patients with or without pDSAs
(Figure 2). At 12 months post-transplantation, kidney
function was significantly better in patients without
pDSAs (Figure 3). However, no difference in kidney
function was observed at 24 and 60 months (Figure 3).
Similarly, proteinuria did not differ in the 2 groups at 1
year post-transplantation (P ¼ 0.26, Supplementary
Figure S3). We assessed the predictive factors for kid-
ney graft loss by means of a Cox proportional regres-
sion analysis, including the presence of pDSAs, the
donor and recipient age, the use of polyclonal anti-


























CLKT w/o pDSA CLKT with pDSA KTA
Log-rank : p= 0.1 KTA vs CLKT w/o pDSA
p= 0.1 KTA vs CLKT with pDSA
p= 0.9 CLKT with pDSAs vs. w/o pDSA
CLKT with pDSA n=46                     29                      17                       12                        6                       4
CLKT w/o pDSA n=120                    97                      68                        50                       39                   35
KTA with pDSA n= 86                       64                      51                       40                        25                   10
Figure 2. Death-censored kidney graft survival. CLKT, combined liver-kidney transplantation; KTA, kidney transplant alone; pDSA, preformed
donor-specific anti–human leukocyte antigen antibody.
A Del Bello et al.: CLKT With or Without pDSA CLINICAL RESEARCHtransplantation, and kidney retransplantation. We
found no significant associated factor for kidney graft
loss after CLKT.
The frequency of biopsy-proven kidney rejection
episodes was significantly higher in patients with
pDSAs (Figure 4). During the follow-up, 5 patients in
each group had a biopsy-proven kidney rejection: 5
AMRs in CLKT recipients with pDSAs and 4 acute T-
cell–mediated rejections and 1 AMR related to the
occurrence of de novo DSAs in CLKT recipients without
pDSAs. Hence, the incidence of AMR was significantly
higher in patients with pDSAs (5/46 patients with
pDSAs vs. 1/120 patients without pDSAs, P ¼ 0.007).
Among patients with pDSAs, the rate of biopsy-
proven kidney rejection in patients transplanted with
a positive (T and/or B cells) XM was not significantly
different compared with patients transplanted with a
negative XM (3/13 vs 2/33, P ¼ 0.13). Kidney graft
survival was similar in patients with a positive or
negative XM (3 patients in both groups reverted to
dialysis), and kidney graft function was similar in both
groups 1 and 5 years post-transplantation (53  21 and
48  27 ml/min per 1.73 m2 in patients transplanted
with a positive XM and 46  20 and 44  13 ml/min/
1.73 m2 in patients with a negative XM, P ¼ not
significant).
We assessed predictive factors for rejection by
means of a Cox proportional regression analysis,
including pDSAs, the use of polyclonal antibodies, the
donor age, the class, and the number of DSAs at
transplantation. We found no significant associated
factor for kidney graft rejection after CLKT in this
model.
All 5 rejections in patients with pDSAs were
considered to be AMRs. All but 1 were treated withKidney International Reports (2020) 5, 2202–2211steroid pulses, plasma exchanges, rituximab perfusion
(375 mg/m2, 2 doses), and intravenous Igs (2 g/kg). The
last patient received steroid pulses, eculizumab (900
mg/wk for 1 month and then 1200 mg every 2 weeks)
for 6 months, and bortezomib (1.3 mg/m2, twice weekly
in 4 perfusions). At the last follow-up (i.e., 23 [range 4–
133] months postrejection), 4 of the 5 patients had
preserved kidney function. Only 1 patient, who
experienced AMR and a recurrence of type I hyper-
oxaluria, reverted to dialysis 8 months post-
transplantation (7 months after kidney rejection).
Among patients without pDSAs, only 1 presented with
an acute AMR with detectable anti–class II de novo anti-
HLA DSAs and reverted to dialysis 4 months post-
rejection despite treatment with plasma exchanges and
steroid pulses. All 4 other rejections were considered to
be steroid-sensitive, T-cell–mediated rejections and
reserved a functional kidney transplant at the last
follow-up (51 [range 22–102] months after kidney
rejection).
Kidney Transplant Outcome in CLKT Versus
KTA Recipients
Death-censored kidney graft survival did not differ
between CLKT and KTA recipients with pDSAs
(Figure 2). It did not statistically differ with that
observed in CLKT without pDSAs. Kidney function
was significantly better in CLKT without pDSAs at 1
year after the transplantation compared with both
groups (CLKT and KTA) with pDSAs (Figure 3). How-
ever, no difference between all 3 groups was observed
at 5 years post-transplantation (Figure 3). Conversely,
the graft rejection rate was significantly higher in pa-
tients who received a KTA with pDSAs compared with
patients who received a CLKT with or without pDSAs2207
Figure 3. Modification of Diet in Renal Disease (MDRD) estimated
glomerular filtration rate (GFR) at years 1, 2, and 5 post-
transplantation.
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significantly higher in KTA recipients with pDSAs (25/
86 KTA with pDSAs [29%]) compared with CLKT with
pDSAs (5/46 [11%], P ¼ 0.03).
We analyzed kidney histologic features observed on
1-year protocol kidney biopsies. Microvascular
inflammation, transplant glomerulopathy, and C4d
positivity tended to be more prevalent in KTA re-
cipients with pDSAs compared with CLKT with pDSAs
(Supplementary Figure S4).
Immunologic Follow-Up
Sixteen of the 46 patients (35%) with pDSAs were
tested for the presence of HLA antibodies 1 month
post-transplantation. Four of the 6 patients (67%) with
only anti–class I pDSA, 3 of the 5 (60%) patients with
only anti–class II pDSAs, and 4 of the 5 (80%) patients
with both anti–class I and II pDSAs still had detectable
DSAs.
Among the 46 patients with pDSAs, 22 patients
(48%) were retested for anti-HLA DSA at least once
after transplantation. At the last anti-HLA screening
(i.e., 17 [range 1–63] months post-transplantation), 3 of
9 (33%), 5 of 8 (63%), and 4 of 5 (80%) patients with
anti–class I, anti–class II, and both anti–class I and II
pDSAs, respectively, still had detectable DSAs.
De novo DSAs were detected in 10 of the 82 patients
without pDSAs who were tested for anti-HLA anti-
bodies after transplantation. Only 1 of these patients
developed an AMR. Of note, none of the 21 recipients
with pDSAs tested after transplantation developed de
novo DSAs.
DISCUSSION
The number of CLKTs performed each year has
increased over the past decades.12 Therefore, the
question of whether or not a double transplantation is
acceptable for a recipient with pDSAs is not uncom-
mon. In our series, 28% of the CLKT recipients pre-
sented with pDSAs at transplantation, a proportion
that corresponds with previous reports.13,14 The
improvement in patient and graft survival in case of
CLKT compared with sequential transplantations
highlights the immunologic protective effect of the
liver on kidney grafts.15 However, the deleterious ef-
fect of pDSAs in sensitized recipients with a positive
XM was previously raised by some registry analyses.5,6
Our data are consistent with these results demon-
strating a lower rate of recipient survival in case of
pDSAs, but, interestingly, even if the presence of DSA
with an MFI higher than 5000 and the presence of 3 or
































Log-rank: p<0.001 CLKT without pDSAs vs KTA with DSAs
p<0.001 CLKT with pDSAs vs KTA with DSAs
p= 0.04 CLKT with pDSAs vs without pDSAs
CLKT with pDSAs n=46                           29                            17                       12                          6          4
CLKT w/o pDSAs n= 120                        97                            68                        50                         39          35
KTA with pDSAs n=86                            64                             51                       40                         25        10
Figure 4. Survival without kidney graft rejection. CLKT, combined liver-kidney transplantation; KTA, kidney transplant alone; pDSA, preformed
donor-specific anti–human leukocyte antigen antibody.
A Del Bello et al.: CLKT With or Without pDSA CLINICAL RESEARCHsurvival, these factors were not associated with kidney
rejection or liver failure. One could argue that patients
with pDSAs received a high level of immunosuppres-
sion compared with other patients, leading to more
infectious, cardiovascular, and neoplastic events.
Recently, Kamal et al.16 performed a registry analysis
from the OPTN database to investigate the role of in-
duction after CLKT. They did not find any effect of
induction therapy on patients’ and allografts’ sur-
vivals. However, in patients who received T-cell–
depleting induction therapy, CNI-based immunosup-
pression was associated with decreased patients’ sur-
vival and both liver and kidney transplants’ survival.
This is in line with our study in which the large ma-
jority of CLKT recipients with pDSAs were given T-
cell–depleting induction therapy and CNI-based
maintenance immunosuppression. Further prospective
studies are needed to assess the optimal induction
therapy agent after CLKT. In a previous single-center
retrospective analysis of 86 CLKT recipients
(including 30 with pDSAs), O’Leary et al.13 reported
that anti–class II DSAs were associated with a poorer
rate of patient survival and an increased risk of both
liver and kidney graft losses. In our study, liver graft
survival with pDSAs was excellent and was similar to
CLKT patients without pDSAs and to liver transplant
alone recipients with preformed DSAs. Moreover, the
death-censored kidney graft survival did not differ
according to the presence or absence of pDSAs. In
addition, kidney AMR was infrequent after CLKT even
in case of pDSA with a positive XM. The incidence of
kidney graft failure related to AMR was rare. We
observed only 1 case of graft failure in a patient who
presented with an AMR associated with a recurrence of
hyperoxaluria. Similarly, we observed no liver failure
related to graft rejection. However, we were unable toKidney International Reports (2020) 5, 2202–2211assume that some of the cases of arterial thrombosis
were associated with an alloimmune phenomenon. To
note, in the O’Leary et al. study,13 the reasons for liver
transplantation were different from ours. In their
study, a high proportion of patients were infected by
hepatitis C virus.
We also compared the outcome of CLKT with pDSAs
and kidney transplant patients alone with DSAs.
Despite a higher proportion of positive XMs at trans-
plantation and significantly lesser use of apheresis,
rituximab, polyclonal antibodies, tacrolimus, and ste-
roids in the CLKT group, kidney graft survival during
the follow-up and graft function at 5 years after
transplantation did not statistically differ between the
groups. Furthermore, the AMR rate was significantly
higher in patients who received a kidney transplant
alone (29% vs. 11%, P ¼ 0.03). This is in line with a
recent study by Taner et al.17 that described the
outcome of 68 CLKTs (including 14 with pDSAs) and
compared them with 136 kidney transplant recipients
(including 28 patients with pDSAs). They found a
higher AMR rate in patients with isolated kidney
transplantation (46%) compared with CLKT recipients
(7%). Thereafter, the same group described a unique
evolution of the transcriptome in protocol kidney bi-
opsies from CLKTs with pDSAs showing less inflam-
mation or endothelial activation and an increase in the
expression of genes related to tissue integrity compared
with those observed in isolated kidney transplant pa-
tients with pDSAs18 but also a donor-specific hypo-
responsiveness after CLKT not observed in isolated
kidney transplant recipients.19 All of these data sup-
port the relative safety of CLKT with pDSAs in terms of
liver and kidney graft survival.
In our study, the incidence of de novo DSAs was
similar to that observed after isolated kidney or liver2209
CLINICAL RESEARCH A Del Bello et al.: CLKT With or Without pDSAtransplantation.20,21 However, the incidence of
antibody-mediated liver or graft rejection was lower
than in isolated transplantation because only 1 of the 10
recipients who developed de novo DSAs presented an
AMR. Recently, in a cohort of 83 CLKTs, Parajuli
et al.22 reported that 23 of 83 patients developed de
novo DSAs during the follow-up, but de novo DSA
occurrence was not associated with graft failure of the
kidney or liver. Further analyses are required to
explain this difference. Interestingly, we also reported
that no patients with pDSAs developed de novo DSAs in
our cohort.
Our present study has several limitations. First, it is
a retrospective study of 8 high-volume European
transplant centers. Therefore, the management of these
patients was quite different, and potential confounding
factors such as the presence of residual renal function
at transplantation or different local practice to propose
isolated liver or kidney transplantation versus com-
bined transplantation were not evaluated. Neverthe-
less, through this study, the outcome of CKLD in a real-
life setting can be described. Second, DSAs were not
tested with complement-binding tests or Ig subclasses,
which are supposed to improve the specificity of DSAs
after kidney and liver transplantation,2,23 and we used
the 2 different available Luminex single-antigen bead
assays (Immucor Lifecodes used in Lyon Hospital and
One Lambda Labscreen used in the other centers) to
detect anti-HLA antibodies. However, it was previ-
ously shown that these assays lead to comparable re-
sults and that the MFI is 50% lower in the the Immucor
assay compared with the One Lambda assay.9 In the
end, we only assessed the role of A/B/DR/DQ DSA in
our cohort and did not evaluate the role of Cw or DP
antibodies after CLKT. However, we excluded patients
who had only anti-Cw or anti-DP antibodies from the
analysis. Third, because all participating centers
assessed rejection using kidney rather than liver bi-
opsies, we only reported on isolated liver rejections,
which could result in the underdiagnosis of the real
incidence of liver graft rejection (and therefore, some
liver AMR) in this cohort. Moreover, the absence of a
difference in the liver transplant rejection rate and the
histologic pattern observed in the 1-year biopsies after
CLKT versus KTA with pDSAs could be related to the
small number of patients. Notwithstanding, in light of
the liver graft outcome, the impact of liver graft
rejection related to the presence of pDSAs seems to be
limited, and despite the small sample size, biopsies
from KTA tended to show more antibody-related le-
sions in the pDSA group.
In conclusion, CLKT with pDSA seems to be asso-
ciated with a higher mortality rate, even if the direct
role of DSAs remains elusive. Nevertheless, this2210procedure is also associated with good mid- to long-
term liver and kidney graft survival. The reasons for
the high mortality rate as well as optimal induction and
maintenance therapy in this context should be
explored in further prospective large studies.DISCLOSURE
All the authors declared no competing interests.
SUPPLEMENTARY MATERIAL
Supplementary File (PDF)
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Figure S2. Patient survival after combined liver-kidney
transplantation (CLKT) or liver transplantation alone
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